The estimated Net Worth of Douglas Fambrough is at least 17.7 百万$ dollars as of 15 December 2021. Douglas Fambrough owns over 13,750 units of Dicerna Pharmaceuticals Inc stock worth over 9,049,693$ and over the last 11 years he sold DRNA stock worth over 3,614,546$. In addition, he makes 5,048,130$ as President、 Chief Executive Officer、 Director at Dicerna Pharmaceuticals Inc.
Douglas has made over 9 trades of the Dicerna Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 13,750 units of DRNA stock worth 525,525$ on 15 December 2021.
The largest trade he's ever made was exercising 179,865 units of Dicerna Pharmaceuticals Inc stock on 10 December 2021 worth over 600,749$. On average, Douglas trades about 21,710 units every 158 days since 2013. As of 15 December 2021 he still owns at least 236,779 units of Dicerna Pharmaceuticals Inc stock.
You can see the complete history of Douglas Fambrough stock trades at the bottom of the page.
Dr. Douglas M. Fambrough Ph.D. is President, Chief Executive Officer, Director of the Company. From 2000 to May 2010, Dr. Fambrough held various positions at Oxford Bioscience Partners, a life science venture capital firm, most recently as a general partner. During his years at Oxford Bioscience Partners, he specialized in financing innovative life science technology companies, including the Company, Sirna Therapeutics, Inc. (acquired by Merck & Co., Inc.), Solexa, Inc. (acquired by Illumina, Inc.), and Xencor, Inc. (NASDAQ: XNCR), and served as a director of each of these companies. Dr. Fambrough has also served as a Trustee of Boston Biomedical Research Institute, a not-for-profit organization. Before joining Oxford Bioscience Partners, he was a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute). Dr. Fambrough graduated from Cornell University and obtained his Ph.D. in genetics at the University of California, Berkeley. The Nominating and Corporate Governance Committee believes that Dr. Fambrough’s experience serving as our President and Chief Executive Officer and as a member of our Board of Directors, combined with his experience in the venture capital industry and biotechnology research and development, provide him with the qualifications and skills to serve as a member of our Board of Directors.
As the President、 Chief Executive Officer、 Director of Dicerna Pharmaceuticals Inc, the total compensation of Douglas Fambrough at Dicerna Pharmaceuticals Inc is 5,048,130$. There are no executives at Dicerna Pharmaceuticals Inc getting paid more.
Douglas Fambrough is 51, he's been the President、 Chief Executive Officer、 Director of Dicerna Pharmaceuticals Inc since 2010. There are 10 older and 2 younger executives at Dicerna Pharmaceuticals Inc. The oldest executive at Dicerna Pharmaceuticals Inc is Patrick Gray, 71, who is the Independent Director.
Douglas's mailing address filed with the SEC is C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE, MA, 02139.
Over the last 11 years, insiders at Dicerna Pharmaceuticals Inc have traded over 233,644,011$ worth of Dicerna Pharmaceuticals Inc stock and bought 2,456,100 units worth 36,501,331$ . The most active insiders traders include Capital Management, Llc Kol...、Nicole Vitullo、Peter Kolchinsky. On average, Dicerna Pharmaceuticals Inc executives and independent directors trade stock every 21 days with the average trade being worth of 4,025,674$. The most recent stock trade was executed by Douglas W. Pagan on 15 December 2021, trading 2,050 units of DRNA stock currently worth 78,351$.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using its proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of its flagship liver-based GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to its own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and its collaborative partners, they currently have more than 20 active discovery, preclinical or clinical programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. Dicerna's mission is to interfere - to silence genes, to fight disease, to restore health.
Dicerna Pharmaceuticals Inc executives and other stock owners filed with the SEC include: